This conclusion is based on a spatial functional genomics screen (Perturb‐map) performed in preclinical ovarian cancer models, which recapitulated tumor heterogeneity and revealed that IL‐4 directs localized TME composition, driving clonal selection and immunotherapy resistance. Here, IL4 is linked to ovarian carcinoma.